Mary Caffrey

5 days ago | ajmc.com | Mary Caffrey

Patients with polycythemia vera (PV) may soon be spared repeat phlebotomies, following results that show a new therapy prevented the buildup of excess blood cells and eased painful symptoms. Adding rusfertide to standard of care more than doubled share of patients with PV who did not meet criteria for a phlebotomy, according to data from the VERIFY trial (NCT05210790), presented Sunday during the plenary session of the American Society of Clinical Oncology (ASCO).

6 days ago | ajmc.com | Mary Caffrey

An analysis from the CEPHEUS trial shows that patients newly diagnosed with multiple myeloma (NDMM) who were not eligible for transplant and received a daratumumab-based regimen had deep and durable responses, with median progression-free survival (PFS) not reached after almost 5 years.1This new look at CEPHEUS data came during an oral abstract session Monday at the American Society of Clinical Oncology annual meeting. The study’s lead author, Saad Z.

1 week ago | ajmc.com | Mary Caffrey

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab (Imfinzi; AstraZeneca) and chemotherapy both before and after surgery were more likely to be alive and event-free after 2 years than those receiving chemotherapy only, findings released Sunday show.1 The phase 3 MATTERHORN trial (NCT04592913), to be presented at the plenary session of the American Society of Clinical Oncology (ASCO) annual meeting, shows that following...

1 week ago | ajmc.com | Mary Caffrey

Biomarker testing for early-stage patients with nonsquamous non-small cell lung cancer (NSCLC) allowed investigators to find and treat those patients who would benefit from chemotherapy after surgery, even though traditional guidelines would not suggest it. The result? Patients who were treated were 78% less likely to see their disease return, compared to a similar group not given chemotherapy.

1 week ago | ajmc.com | Mary Caffrey

Monitoring symptoms can help keep patients with cancer out of the hospital—but programs only work if patients and other providers are equally engaged in this process, according to presenters at a session on quality care and health services research held Friday during the American Society of Clinical Oncology 2025 Annual Meeting.